Show simple item record

dc.contributor.authorDavidson, Isobel
dc.contributor.authorRobinson, S. D.
dc.contributor.authorHarding, S. A.
dc.contributor.authorCummins, P.
dc.contributor.authorDin, J. N.
dc.contributor.authorSarma, J.
dc.contributor.authorFox, K. A. A.
dc.contributor.authorBoon, N. A.
dc.contributor.authorNewby, D. E.
dc.identifier.citationDavidson, I., Robinson, S., Harding, S., Cummins, P., Din, J., Sarma, J., Fox, K., Boon, N. & Newby, D. (2006) Functional interplay between platelet activation and endothelial dysfunction in patients with coronary heart disease, Platelets, vol. 17, , pp. 158-162,
dc.description.abstractPlatelet-monocyte binding and surface P-selectin expression are sensitive markers of platelet activation. Endothelium-derived factors are known to inhibit platelet activation and may confer important anti-atherothrombotic effects. We assessed the relationship between platelet activation and endothelium-dependent vasomotion in patients with coronary heart disease (CHD). Twenty male patients with stable CHD were compared with 20 healthy men. Platelet-monocyte binding and platelet surface expression of P-selectin were assessed using two-colour flow cytometry on whole blood. Forearm blood flow was assessed in patients using venous occlusion plethysmography during intra-arterial infusions of substance P, acetylcholine and sodium nitroprusside. Platelet activation was higher in patients than healthy men (platelet-monocyte binding, 27--3 vs. 20--1%; P-<-0.05). In patients with CHD, there was an inverse correlation between maximal substance P induced vasodilatation and both platelet-monocyte binding (P-=-0.003) and P-selectin expression (P-=-0.02). A similar correlation was observed between platelet-monocyte binding and the vasomotor response to acetylcholine (P-=-0.08) but not with sodium nitroprusside. In patients with stable coronary heart disease, there is a strong inverse relationship between markers of platelet activation and endothelium-dependent vasomotor function. This may explain the pathophysiological mechanism linking endothelial vasomotor dysfunction and the risk of acute atherothrombotic events.
dc.publisherTaylor & Francis
dc.subjectcoronary disease
dc.subjectendothelial function
dc.subjectforearm blood flow
dc.titleFunctional interplay between platelet activation and endothelial dysfunction in patients with coronary heart disease
dc.description.referencetext1. Rinder H, Bonan J, Rinder C, et al. Dynamics of leukocyteplatelet adhesion in whole blood. Blood 1991;78:1730-1737. 2. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171. 3. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358. 4. Mickelson JK, Lakkis NM, Villarreal-Levy G, et al. Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?. J Am Coll Cardiol 1996;28:345-353. 5. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term followup of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954. 6. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658. 7. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-1415. 8. Rosenblum WI. Platelet adhesion and aggregation without endothelial denudation or exposure of basal lamina and/or collagen. J Vasc Res 1997;34:409-417. 9. Diodati JG, Dakak N, Gilligan DM, et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998;98:17-24. 10. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38:1002-1006. Platelet activation and endothelial dysfunction 161 11. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. PNAS 1996;93:11877-11882. 12. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104:1533-1537. 13. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23:2131-2137. 14. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. PNAS 1994; 91:8767-8771. 15. Elstad MR, La TR, Cowley FS, et al. P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol 1995;155:2109-2122. 16. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E platelet adhesion and aggregation without endothelial denudation or exposure of basal lamina and/or collagen. Nat Med 2003; 9:61-67. 17. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-720. 18. Heitzer T, Ollmann I, Koke K, et al. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation 2003;108:536-541.
qmu.authorDavidson, Isobel

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record